SynthesisSleep & breathing = Schlaf & Atmung2026
Prevalence and clinical characteristics of sleep apnea in hypertrophic cardiomyopathy: A meta-analysis.
Synthesis in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo investigate the prevalence and clinical characteristics of sleep apnea (SA) in patients with hypertrophic cardiomyopathy (HCM).
methodsEligible studies were screened and selected from four databases. The pooled prevalence of SA in HCM was calculated and presented as proportion with 95% confidence intervals (CI). Comparison of clinical characteristics between HCM patients with or without SA was then assessed and presented as mean difference (MD) or odds ratio (OR) with 95%CI. Sensitivity analyses, subgroup analyses and meta-regression were then applied for heterogeneity assessment.
resultsEight studies with 3,922 HCM patients was included, revealing an SA prevalence of 53% (95% CI 39%, 67%). HCM patients with SA were associated with older age (MD 8.91, 95% CI 7.28, 10.54), male (OR 1.59, 95%CI 1.30, 1.95). elevated body mass index (MD 2.59, 95%CI 1.36, 3.81), smoking (OR 1.86, 95%CI 1.39, 2.49), hypertension (OR 2.54, 95%CI 2.06, 3.14), diabetes (OR 2.03, 95%CI 1.31, 3.13) and atrial fibrillation (OR 1.96, 95%CI 1.51, 2.54). Echocardiographic findings revealed that HCM with SA was associated with reduced interventricular septum thickness (MD -1.25, 95%CI -2.44, -0.06), increased left atrial diameter (MD 1.48, 95%CI 0.49, 2.47) and left ventricular end-diastolic diameter (MD 2.81, 95%CI 1.99, 3.62). Additionally, HCM patients with SA showed increased application of hypertensive drugs, and application of calcium channel blockers was identified as source of heterogeneity in meta-regression.
conclusionSA is highly prevalent in HCM, and HCM patients with comorbid SA exhibit distinct baseline characteristics, cardiac structure and drug application.
Indexed as
Identifiers
42260027What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.